´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼¿ï ±Ý°È¦
±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium
ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 010-8584-0193
À̸ÞÀÏ : gaonpco@gaonpco.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À°
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 1Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë)
Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼¿ïÀÇ´ë)
Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø)
Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´)
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)
Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼¹Î¼®(¼¿ïÀÇ´ë)